In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lilly and Sanofi collaborate on colon cancer treatment

Executive Summary

Eli Lilly and Sanofi will collaborate in the US to register, develop, and market Eloxatin (oxaliplatin), Sanofi's new platinum- based treatment for use in combination with 5-FU for all forms of advanced metastatic colorectal cancer. Sanofi has rights to the drug under license from Debiopharm SA.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies